Company intelligence / Profile preview

Bioverativ Inc.

Waltham, Massachusetts, United Statessanofi.com ↗

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

Bioverativ had two commercial products for hemophilia treatment (Eloctate and Alprolix) that generated approximately $850 million in sales in 2016. The company was acquired by Sanofi in 2018.

Therapeutic areas: Hematology
Modalities: Biologics
Industry: Biotech

Drug pipeline

4 assets

Eloctate

Commercial

Indications: Hemophilia A

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Bioverativ Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioverativ Inc..

Explore the full profile